ClinicalTrials.gg
CompletedNCT05511922Updated Jun 8, 2026

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

A Phase 3 interventional study of KVD900 600 mg and Drug: KVD900 300 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 61 sites in 17 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Started
2022
with 2 others
Phase 3
4 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is one of 3 that started in 2022, is one of 4 in phase 3, and was the 6th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • KONFIDENT-S
  • Sebetralstat
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adolescent patient 12 to 17 years of age at the time of enrollment and during sample collection in this PK subtrial.
  • Patient is currently participating in KVD900-302.
  • Patient must provide signed or assent (when applicable), and a legally authorized representative (LAR) must also provide signed informed consent when applicable.
  • Patient and LAR are willing and able to provide samples per the requirements of the protocol, including willingness to complete forms and the electronic Diary, obtain and return samples in a timely manner, and obtain samples while within the required age limit.

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of any bleeding disorder or currently taking any anti-coagulant or anti- agent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    KVD900 600 mg

    Drug: KVD900 600 mg

  • Experimental
    Experimental: KVD900 300 mg

    Drug: Drug: KVD900 300 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax

    Time frame: Up to 6 hours after IMP administration

  2. Pharmacokinetics - Tmax

    Time frame: Up to 6 hours after IMP administration

  3. Pharmacokinetics - AUC

    Time frame: Up to 6 hours after IMP administration

07

Study locations

61 sites
  • KalVista Investigative Site
    Scottsdale, Arizona 85251, United States
  • KalVista Investigative Site
    Little Rock, Arkansas 72205, United States
  • KalVista Investigative Site
    San Diego, California 92122, United States
  • KalVista Investigative Site
    San Diego, California 92123, United States
  • KalVista Investigative Site
    Santa Monica, California 90404, United States
  • KalVista Investigative Site
    Centennial, Colorado 80112, United States
  • KalVista Investigative Site
    Colorado Springs, Colorado 80907, United States
  • KalVista Investigative Site
    Evansville, Indiana 47715, United States
  • KalVista Investigative Site
    Overland Park, Kansas 66211, United States
  • KalVista Investigative Site
    Louisville, Kentucky 40215, United States
  • KalVista Investigative Site
    Chevy Chase, Maryland 20815, United States
  • KalVista Investigative Site
    Plymouth, Minnesota 55446, United States
  • KalVista Investigative Site
    St Louis, Missouri 63141, United States
  • KalVista Investigative Site
    Charlotte, North Carolina 28277, United States
  • KalVista Investigative Site
    Cincinnati, Ohio 45236, United States
  • KalVista Investigative Site
    Toledo, Ohio 43617, United States
  • Kalvista Investigative Site
    Hershey, Pennsylvania 17033, United States
  • KalVista Investigative Site
    Dallas, Texas 75231, United States
  • KalVista Investigative Site
    Layton, Utah 84041, United States
  • KalVista Investigative Site
    Spokane, Washington 99204, United States
  • KalVista Investigative Site
    Campbelltown, 2560, Australia
  • KalVista Investigative Site
    Vienna, 1090, Austria
  • KalVista Investigative Site
    Sofia, 1431, Bulgaria
  • KalVista Investigative Site
    Montreal, H2W 1R7, Canada
  • KalVista Investigative Site
    Grenoble, 38043, France
  • KalVista Investigative Site
    Lille, 59037, France
  • KalVista Investigative Site
    Paris, 75012, France
  • KalVista Investigative Site
    Berlin, 12203, Germany
  • KalVista Investigative Site
    Frankfurt, 60590, Germany
  • KalVista Investigative Site
    Mainz, 55131, Germany
  • KalVista Investigative Site
    Mörfelden-Walldorf, 64546, Germany
  • KalVista Investigative Site
    Athens, 11521, Greece
  • KalVista Investigative Site
    Athens, 11527, Greece
  • KalVista Investigative Site
    Haifa, 31048, Israel
  • KalVista Investigative Site
    Petach Tikvah, 4920235, Israel
  • KalVista Investigative Site
    Ramat Gan, 52621, Israel
  • KalVista Investigative Site
    Tel Aviv, 64239, Israel
  • KalVista Investigative Site
    Sapporo, Hokkaido 002-8072, Japan
  • KalVista Investigative Site
    Chiba, 260-8677, Japan
  • KalVista Investigative Site
    Hiroshima, 730-8518, Japan
  • KalVista Investigative Site
    Kawagoe-shi, 350-8550, Japan
  • KalVista Investigative Site
    Maebashi, 371-8511, Japan
  • KalVista Investigative Site
    Soka-shi, 340-0041, Japan
  • KalVista Investigative Site
    Takatsuki-shi, 569-8686, Japan
  • KalVista Investigative Site
    Tokyo, 142-8666, Japan
  • KalVista Investigative Site
    Yokohama, 236-0004, Japan
  • KalVista Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • KalVista Investgative Site
    Auckland, 1023, New Zealand
  • KalVista Investigative Site
    Sângeorgiu de Mureş, 547530, Romania
  • KalVista Investigative Site
    Martin, 036 59, Slovakia
  • KalVista Investigative Site
    Cape Town, 7700, South Africa
  • KalVista Investigative Site
    Barcelona, 08035, Spain
  • KalVista Investigative Site
    Barcelona, 08907, Spain
  • KalVista Investigative Site
    Madrid, 28046, Spain
  • KalVista Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • KalVista Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
  • KalVista Investigative Site
    Cardiff, CF14 4XW, United Kingdom
  • KalVista Investgative Site
    Frimley, GU16 7UJ, United Kingdom
  • KalVista Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • KalVista Investigative Site
    London, E1 2ES, United Kingdom
  • KalVista Investigative Site
    London, NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Data will not be shared until all global regulatory filings are complete.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2026, 43 months.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 43 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 23, 2022
StartActual
Oct 24, 2022
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05511922
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Oct 24, 2022
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Jun 8, 2026

Study contacts

Study Director
study director · KalVista Pharmaceuticals, Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebetralstat

Start the discussion